Marinus Pharmaceuticals insider Gail M. Farfel Sells 30,000 Shares (MRNS)

Print 24 April 2015
Seth Barnet / WKRB News

Marinus Pharmaceuticals (NASDAQ:MRNS) insider Gail M. Farfel sold 30,000 shares of Marinus Pharmaceuticals stock on the open market in a transaction that occurred on Tuesday, April 21st. The stock was sold at an average price of $9.48, for a total value of $284,400.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Separately, analysts at Oppenheimer reiterated an “outperform” rating and set a $12.00 price target on shares of Marinus Pharmaceuticals in a research note on Monday, March 16th.

Shares of Marinus Pharmaceuticals (NASDAQ:MRNS) traded up 1.22% on Friday, hitting $9.15. 3,750 shares of the company’s stock traded hands. Marinus Pharmaceuticals has a 52-week low of $4.00 and a 52-week high of $16.60. The stock has a 50-day moving average of $9. and a 200-day moving average of $9.. The company’s market cap is $129.92 million.

Marinus Pharmaceuticals (NASDAQ:MRNS) last released its earnings data on Thursday, March 12th. The company reported $0.62 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $1.01. Analysts expect that Marinus Pharmaceuticals will post $-1.87 EPS for the current fiscal year.

Marinus Pharmaceuticals, Inc is a clinical stage biopharmaceutical company. The Company is focused on developing and commercializing neuropsychiatric therapeutics. Its clinical stage product candidate, ganaxolone, is a small molecule that is a synthetic analog of allopregnanolone, an endogenous neurosteroid produced in the central nervous system that modulates the brain neurotransmitter gamma-aminobutyric acid (NASDAQ:MRNS).

Source

Return